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long-term medical costs. RESULTS: Using 30-day mor-
tality data from the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coro-
nary Arteries (GUSTO) trial, the baseline analysis yielded
an ICER for t-PA of $24,882/QALY compared to SK.
The ICER was sensitive to the difference in reinfarction
rate (baseline 3.83%: 3% ICER $19,326: 6% ICER
$120,767) and mortality rate (baseline 6.3%: 6.7%
ICER $46,688: 7.2% ICER $197,850) of t-PA. CON-
CLUSION: t-PA is a cost-effective therapy for MI com-
pared to SK. In addition, despite using costs and utilities
from varied sources, and employing a simpler model the
findings support previously published results.
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OBJECTIVES: The medical device implantation tech-
niques via percutaneous aboard tend to substitute to sur-
gical techniques, in various cardio-vascular therapeutics.
However, prosthesis implantation is often accompanied
high implementation costs (linked to the device acquisi-
tion) which are difficult to justify to the decision-maker,
in a context of high financial constraint. METHOD:
Available clinical data show similarity of effectiveness
and complication rates between these two techniques.
Therefore, the economic appraisal consists in a cost mini-
mization approach. First, we modeled the two technique
protocols before costing each action (personnel, facili-
ties, . . . ) according to the internal costs of Grenoble
hospital. Moreover, we estimated the budgetary produc-
tivity of these two strategies using the French DRG classi-
fication system used to adjust the annual financial alloca-
tion of French public hospitals. RESULTS: Results show
the percutaneous technique (septal occluder Amplatzer®)
is dominant (1.5 times less expensive than surgery),
mainly by decreasing the hospital stay (two hospitaliza-
tion days instead of 12 days in the surgery strategy).
DRG system classification generates 1473 ISA (hospital
productivity index) for the percutaneous technique and
7556 ISA for invasive surgery. CONCLUSIONS: Com-
paring between cost-minimization technic using internal
costs and incremental budgetary impact using French
DRG classification, we conclude that the prosthesis im-
plantation via percutaneous aboard is economically dom-
inant (cheaper than invasive surgery) but 5 times less
contributive to annual budget allocation. Therefore in-
citation for the hospital decision-maker to use septal
occluders must come with the adaptation to new techno-
logies of financial public allocation using the DRG classi-
fication.
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OBJECTIVE: To assess medication compliance and pre-
dictors of compliance with HMG-CoA reductase inhibi-
tors for patients following a myocardial infarction (MI)
or other atherosclerotic event. METHODS: Patients were
identified from a managed care organization (MCO) da-
tabase who had an MI or other atherosclerotic event in
1997 or 1998 and were continuously enrolled in the
MCO for the year following the event. All patient records
were collected following guidelines for HEDIS reporting.
Pharmacy claims data review identified 216 patients who
had at least one prescription filled for a statin. A number
of compliance measures were calculated, including the
CMA, a continuous multiple-interval measure of medica-
tion availability. A multivariate linear regression of CMA
included the following independent variables: age, sex,
ICD-9 of admission, DRG of admission, statin prescribed,
medication days supply dispensed, number of unique
medications prescribed, number of unique chronic medi-
cations prescribed, and prescription drug copay amount.
RESULTS: The mean CMA was 0.820. Regression re-
sults (adjusted r-square 0.11) indicate that several factors
had potentially large impacts on CMA, but the estimates
were associated with large standard errors (age, gender,
ICD-9 of admission, DRG of admission, statin pre-
scribed). Four factors with estimates statistically signifi-
cantly different from zero are as follows (t-statistics in
parentheses): days supply (each 30-day increment) 0.116
(3.61), number of concomitant unique medications 0.009
(2.29), number of concomitant unique chronic medica-
tions 0.012 (1.83), copay (each $1) 0.007 (2.84). CON-
CLUSIONS: Compliance with statins was high in this
sample, but not ideal (1.0). Strategies for improving com-
pliance that may have merit include: providing patients
with 60 or 90-day supplies (rather than 30-day supplies),
controlling the number of other medications prescribed
and having lower patient copayments for these important
medications.
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OBJECTIVES: German hospitals receive the same reim-
bursement by the statutory health insurance for CABG
